Krystal Biotech

Krystal Biotech (KRYS) is currently trading at $260.95. The stock has a 52-week range of $123.36 to $291.93 and a market capitalization of $7.63B.

Krystal Biotech has a P/E ratio of 38.2 (forward P/E: 24.7), a dividend yield of none, and 1-year performance of +46.5%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.

There have been 104 insider transactions for KRYS in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.

Krystal Biotech (KRYS) has returned +46.5% over the past 12 months. The stock traded between $123.36 and $291.93 during this period, and is currently at $260.95.

1 tracked hedge funds currently hold KRYS in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.

Krystal Biotech (KRYS) has a market capitalization of $7.63B. The trailing P/E ratio is 38.2 and forward P/E is 24.7. The stock is classified in the Healthcare sector.

Krystal Biotech reported revenue of $389.13M with net income of $204.83M and a profit margin of 0.53%. The stock has a beta of 0.54.

Krystal Biotech (KRYS) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.